EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib, and osimertinib are the standard first-line therapies for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)1.